Compositions and methods for treating HIF-1a over-expressing cancers

US11359008B2 · kind B2 · utility

Assignee

• University of Southern California · US

Inventors

• Wei Li · Lexington, US
• David Woodley · Altadena, US
• Mei Chen · Altadena, US
• Divya Sahu · San Diego, US
• Hangming Dong · 流花街道, CN
• Mengchen Zou · 流花街道, CN

Key dates

• Filing date: Apr 4, 2019
• Grant date: Jun 14, 2022
• Expiry date: Apr 4, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2330/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90α and methods of using the same to treat HIF-1a-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP in Hsp90α or VKHFSVEGQ in Hsp90α.